Otivio’s main product, FlowOx™, is addressing chronic wounds with focus on peripheral arterial disease (PAD), which is a serious condition leading to pain, chronic wounds and in many cases amputation and mortality. The patient population is very large and increasing. There are limited adequate treatment options offered to the patients aside from surgical interventions. FlowOx™ is a non-invasive product intended for home use. Long-term patient testing in more than 50 patients documents increased blood flow, reduced pain and wound healing. FlowOx™ is CE marked. In fourth quarter 2017 had its commercial break-through through sales of FlowOx to public customers.